[HTML][HTML] New-onset IgG autoantibodies in hospitalized patients with COVID-19

…, R Geßner, HM Giannini, J Gonzalez, S Greib… - Nature …, 2021 - nature.com
COVID-19 is associated with a wide range of clinical manifestations, including autoimmune
features and autoantibody production. Here we develop three protein arrays to measure IgG …

[PDF][PDF] Dysgranulopoiesis in patients with coronavirus disease 2019

…, A Burchert, M Gündisch, S Greib… - Acta Haematologica …, 2021 - journals.viamedica.pl
The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus 2 (SARS--CoV-2) was first identified in a group of patients with acute pneumonia …

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 (preprint)

…, R Gessner, HM Giannini, J Gonzalez, S Greib… - 2021 - pesquisa.bvsalud.org
Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2), is associated with a wide range of clinical manifestations, …

The evolutionary making of SARS-CoV-2 (preprint)

…, R Gessner, HM Giannini, J Gonzalez, S Greib… - 2021 - pesquisa.bvsalud.org
Covid-19 is the most devastating pandemic of the past 100 years. A zoonotic transfer
presumably at a wildlife market introduced the causative virus, SARS-CoV-2 (sarbecovirus; beta-…

Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets (preprint)

…, R Gessner, HM Giannini, J Gonzalez, S Greib… - 2021 - pesquisa.bvsalud.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causative agent of COVID-19
pandemic, enters host cells via the interaction of its Receptor-Binding Domain (RBD) of …

Information retrieval in an infodemic: the case of COVID-19 publications (preprint)

…, R Gessner, HM Giannini, J Gonzalez, S Greib… - 2021 - pesquisa.bvsalud.org
… Jung; Sarah C Gilbert; Robin J Shattock; Teresa Lambe; Andrew Gaano; Reinhard
Gessner; Heather M. Giannini; Joyce Gonzalez; Sarah Greib; Margrit Guendisch; Alex Ren …

Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus

…, P Duffau, E Lazaro, C Chapouly, C Greib… - Expert opinion on …, 2010 - Taylor & Francis
Objective: Mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF) and
enteric-coated mycophenolate sodium (EC-MPS), is used to treat systemic lupus …

[HTML][HTML] Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort …

…, D Breilh, P Duffau, E Lazaro, C Greib… - Arthritis research & …, 2010 - Springer
Introduction The aim of this study was to determine whether mycophenolate mofetil (MMF)
pharmacokinetics (PK) under combined MMF and prednisone remission-maintenance therapy …

Pre‐dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases

…, R Legeron, S Bouchet, C Greib… - British Journal of …, 2014 - Wiley Online Library
Aim To date, neither the benefit of mycophenolic acid ( MPA ) therapeutic drug monitoring (
TDM ), the prodrug of mycophenolate mofetil ( MMF ), nor the optimal monitoring technique …

Measurement of total and unbound mycophenolic acid and its glucuronide by LC coupled with MS. Application to a pharmacokinetic study of mycophenolate mofetil in …

S Djabarouti, P Duffau, F Xuereb, E Lazaro, C Greib… - Chromatographia, 2009 - Springer
Liquid chromatography coupled with mass spectrometry for the determination of total and
unbound mycophenolic acid and its major metabolite in human plasma has been developed. …